Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma

医学 倾向得分匹配 放化疗 新辅助治疗 外科 内科学 疾病 食管鳞状细胞癌 人口 肿瘤科 癌症 化疗 乳腺癌 环境卫生
作者
Tae Hee Hong,Tae Ho Kim,Genehee Lee,Jeonghee Yun,Yeong Jeong Jeon,Jung‐Hee Lee,Sumin Shin,Sung Yong Park,Jong Ho Cho,Yong‐Soo Choi,Young Mog Shim,Jong‐Mu Sun,Dongryul Oh,Hong Kwan Kim
出处
期刊:European Journal of Cardio-Thoracic Surgery [Oxford University Press]
卷期号:66 (1)
标识
DOI:10.1093/ejcts/ezae253
摘要

Abstract OBJECTIVES Unlike the initial plan, some patients with oesophageal squamous cell carcinoma cannot or do not receive surgery after neoadjuvant chemoradiotherapy (nCRT). This study aimed to report the epidemiology of patients not receiving surgery after nCRT and to evaluate the potential risk of refusing surgery. METHODS We analysed patients with clinical stage T3-T4aN0M0 or T1-T4aN1-N3M0 oesophageal squamous cell carcinoma who underwent nCRT as an initial treatment intent between January 2005 and March 2020. Patients not receiving surgery were categorized using predefined criteria. To evaluate the risk of refusing surgery, a propensity-matched comparison with those who received surgery was performed. Recurrence-free (RFS) and overall survival (OS) was compared between groups, according to clinical response to nCRT. RESULTS Among the study population (n = 715), 105 patients (14.7%) eventually failed to reach surgery. There were three major patterns of not receiving surgery: disease progression before surgery (n = 25), functional deterioration at reassessment (n = 47), and patient’s refusal without contraindications (n = 33). After propensity-score matching, the RFS curves of the surgery group and the refusal group were significantly different (P < 0.001), while OS curves were not significantly different (P = 0.069). In patients who achieved clinical complete response on re-evaluation, no significant difference in the RFS curves (P = 0.382) and in the OS curves (P = 0.290) was observed between the surgery group and the refusal group. However, among patients who showed partial response or stable disease on re-evaluation, the RFS and OS curves of the refusal group were overall significantly inferior compared to those of the surgery group (both P < 0.001). The 5-year RFS rates were 10.3% for the refusal group and 48.2% for the surgery group, and the 5-year OS rates were 8.2% for the refusal group and 46.1% for the surgery group. CONCLUSIONS Patient’s refusal remains one of the major obstacles in completing the trimodality therapy for oesophageal squamous cell carcinoma. Refusing surgery when offered may jeopardize oncological outcome, particularly in those with residual disease on re-evaluation after nCRT. These results provide significant implications for consulting patients who are reluctant to oesophagectomy after nCRT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
你想读博吗应助run采纳,获得20
1秒前
不安梦桃完成签到 ,获得积分10
2秒前
吴西迪西完成签到,获得积分10
2秒前
1444791378发布了新的文献求助10
2秒前
从容安寒发布了新的文献求助10
3秒前
Orange应助聪明熠彤采纳,获得10
3秒前
3秒前
曾婉娟发布了新的文献求助10
4秒前
4秒前
5秒前
Jason发布了新的文献求助10
7秒前
7秒前
7秒前
劲秉应助壮观雁易采纳,获得10
7秒前
充电宝应助小鹅采纳,获得10
9秒前
loeyyu完成签到,获得积分10
10秒前
帕热达发布了新的文献求助10
10秒前
22发布了新的文献求助10
11秒前
丘比特应助曾婉娟采纳,获得10
12秒前
CodeCraft应助虚心的芷蝶采纳,获得10
12秒前
13秒前
13秒前
王博士完成签到 ,获得积分10
14秒前
可爱的函函应助www采纳,获得10
14秒前
bkagyin应助从容安寒采纳,获得10
15秒前
lulu发布了新的文献求助10
16秒前
16秒前
16秒前
17秒前
lzy发布了新的文献求助10
19秒前
Orange应助loeyyu采纳,获得10
19秒前
KKKKK发布了新的文献求助10
20秒前
22秒前
22秒前
22秒前
22完成签到,获得积分20
22秒前
ZXR发布了新的文献求助10
23秒前
高分求助中
All the Birds of the World 3000
Weirder than Sci-fi: Speculative Practice in Art and Finance 960
IZELTABART TAPATANSINE 500
GNSS Applications in Earth and Space Observations 300
Handbook of Laboratory Animal Science 300
Not Equal : Towards an International Law of Finance 260
A method for calculating the flow in a centrifugal impeller when entropy gradients are present 240
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3720449
求助须知:如何正确求助?哪些是违规求助? 3266557
关于积分的说明 9944688
捐赠科研通 2980278
什么是DOI,文献DOI怎么找? 1634773
邀请新用户注册赠送积分活动 775983
科研通“疑难数据库(出版商)”最低求助积分说明 746093